Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

Positive Coronavirus test results

14 Sep 2020 07:01

RNS Number : 8233Y
Symphony Environmental Tech. PLC
14 September 2020
 

 

 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this information is considered to be in the public domain

 

14 September 2020

SYMPHONY ENVIRONMENTAL TECHNOLOGIES PLC

("Symphony", the "Company" or the "Group")

 

Positive Coronavirus test results in shorter timescales

 

Symphony announced on 23 July that Eurofins Laboratories had tested Symphony's d2p masterbatch incorporated in a polyolefin film, against the bovine form of Coronavirus in accordance with International Standard, ISO 21702-2019, and found a virus reduction of 99.84% in 24 hours.

 

Symphony is now very pleased to announce the results of further Coronavirus tests at 1, 2 and 24 hours, as follows:

 

The Institute of Biology at UNICAMP UNIVERSITY in Sao Paolo State, Brazil ("UNICAMP") has tested polyolefin films incorporating Symphony's antimicrobial d2p masterbatches, according to:

1. ISO 21702-2019 (Measurement of Antiviral Activity on Plastics and other non-porous Surfaces)

2. EN 14476:2013 + A2:2019 (Chemical Disinfectants and Antiseptics - Quantitative Suspension Test Method for Virucidal Activity in Medical Areas)

3. Robert Koch Institute's and Best Laboratory Practices

 

All tests were conducted with biological quadruplicates (four repetitions).

The virus used in the study was the BETACORONAVIRUS Cell: L929 -NCTC clone 929 [L cell, L-929, derivative of Strain L] (ATCC® CCL-1™)(same genus as SARS-CoV-1, SARS-CoV-2, MERS among others). The host cell was a 10% bovine foetal serum.

The contact testing intervals and the antiviral performance were:

A. 1 hour, 99.9% reduction

B. 2 hours 99.99% reduction

C. 24 hours 99.999% reduction

 

UNICAMP concluded in their report that "the products were shown to be virucidal, thus, we recommend the use of such products as potential virucidal agents against coronavirus."

 

It was demonstrated that the active compound was active towards the virus only, and would not harm the host cells.

 

Michael Laurier CEO said: "this is another important breakthrough for Symphony, that leads to an exciting commercial phase that will help accelerate our global sales pipeline for d2p already in development. Plastic, unlike many other materials in common use, can be given anti-microbial properties, and d2p can be included in almost all the plastic products which we touch every day.

 

"These results demonstrate the efficacy against viruses of d2p anti-microbial technology in plastic products, and the importance it has in helping governments to control the spread of the virus, and saving lives. This technology goes beyond short term protections such as washing with soap, sanitising hands, or wiping surfaces; being embedded in the plastic itself, d2p provides protection for the lifetime of the plastic product.

 

"I would like to congratulate our scientific team for developing this remarkable product that we will be moving quickly into our global sales operations."

 

 

Information on UNICAMP UNIVERSITY

https://www.timeshighereducation.com/world-university-rankings/university-campinas

 

 Enquiries

Symphony Environmental Technologies Plc

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

www.symphonyenvironmental.com

Zeus Capital Limited (Nominated Adviser and Joint Broker)

David Foreman / Nick Cowles / Kieran Russell (Corporate Finance)

Tel: +44 (0) 161 831 1512

Dominic King / Victoria Ayton (Sales)

Tel: +44 (0) 203 829 5000

Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

 

Tel: +44 (0) 203 764 2341

The person responsible for arranging the release of this information is Michael Laurier, CEO of the Company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFFIAFIVLII
Date   Source Headline
28th Apr 20267:00 amRNSPre-Close Trading Update
7th Apr 20267:00 amRNS-RHSAC report
23rd Mar 20267:00 amRNSDirector/PDMR dealing - Bed & ISA
18th Feb 20268:28 amRNSNew consultancy agreement and grant of options
12th Jan 20267:00 amRNS-Rd2w Biodegradable Plastic Technology
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSHolding(s) in Company
22nd Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
17th Dec 20253:33 pmRNSTrading and Middle East operations update
28th Nov 20257:00 amRNS-RAlignment with BB-REG-NET's Recommendations
26th Nov 202510:25 amRNSExtension to Convertible Loan Agreements
10th Nov 20257:00 amRNS-RNew product launch, South Korea
29th Oct 20257:00 amRNS-RRoyal Society Study on Ocean Biodegradable Plastic
24th Oct 20257:00 amRNS-RCEO speaks at Argus Fertiliser Conference
16th Oct 20257:00 amRNS-RSuccessful attendance at the K-Show
30th Sep 20257:00 amRNSInterim Results for 6 Months Ended 30 June 2025
26th Sep 20257:00 amRNS-RCEO Speaks at US SPE Conference
19th Sep 20254:55 pmRNSEPA Ireland update
23rd Jul 20251:53 pmRNSResult of AGM
23rd Jul 20257:00 amRNSAGM Statement
8th Jul 202510:25 amRNSUpdate on Approval from the Republic of Ireland
25th Jun 20251:49 pmRNSHolding(s) in Company
23rd Jun 202512:37 pmRNSApproval of d2w products in Ireland
18th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
12th Jun 20257:00 amRNSPreliminary Results
11th Jun 202510:15 amRNSChange of Subscription Amount
5th Jun 20257:00 amRNSChange of Equity Subscriber
14th May 202511:50 amRNSHolding(s) in Company
8th May 202510:35 amRNSEquity Subscription
10th Apr 20259:00 amRNSExtended Scientific Study on Microplastics in Soil
9th Apr 202510:00 amRNSTransfer of Shareholding and Assignment of CLAs
11th Mar 20257:00 amRNS-RStudy Findings - No Trace of Microplastics
10th Mar 20252:21 pmRNSHolding(s) in Company
3rd Mar 20257:00 amRNS-RRuling on Biodegradable Plastic Legislation
23rd Dec 202412:39 pmRNSOption amendments & grant of options
1st Nov 202411:15 amRNSGrant of Options
9th Sep 20247:00 amRNSInterim Results for 6 Months Ended 30 June 2024
23rd Aug 20247:00 amRNSNotice of Results and Investor Presentation
28th Jun 202412:49 pmRNSResult of AGM
28th Jun 20247:00 amRNSAGM Statement
6th Jun 20243:33 pmRNSPosting of Annual Report and Notice of AGM
6th Jun 20243:29 pmRNSPreliminary Results
23rd Apr 20244:36 pmRNSHolding(s) in Company
19th Apr 202411:16 amRNSResult of GM
3rd Apr 20242:00 pmRNSDirector dealing
28th Mar 20244:23 pmRNSResult of PrimaryBid Offer
28th Mar 20242:18 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.